10x Genomics (TXG) Misses Q4 EPS by 9c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TXG Hot Sheet
Join SI Premium – FREE
10x Genomics (NASDAQ: TXG) reported Q4 EPS of ($0.40), $0.09 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $165 million versus the consensus estimate of $153.44 million.
GUIDANCE:
10x Genomics sees Q1 2025 revenue of $610-630 million, versus the consensus of $630.4 million.
For earnings history and earnings-related data on 10x Genomics (TXG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbnb (ABNB) call put ratio 1 call to 1.3 puts into quarter results
- Reynolds Consumer Products Inc. (REYN) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY26 EPS Guidance
- CS Disco, Inc (LAW) Misses Q3 EPS by 6c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
